PMLive12h
Novo shares phase 3 results for obesity candidate CagriSema in diabetes patients
The phase 3 REDEFINE 2 trial has been evaluating once-weekly subcutaneous CagriSema, a fixed dose combination of cagrilintide ...
Endocrinology Advisor7h
Significant Weight Loss Observed With CagriSema in REDEFINE 2 Trial
Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.
NVO Shareholders Have Opportunity to Lead Novo Nordisk A/S Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
NEW YORK, NY / ACCESS Newswire / March 19, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
24/7 Wall St.10h
Novo Nordisk (NVO) Price Prediction and Forecast 2025-2030 (March 2025)
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Novo Nordisk A/S (NVO) Dropped as Trial Results Fell Short of Expectations
Polen Capital, an investment management company, released its “Polen Global Growth Strategy” fourth-quarter 2024 investor ...
Le Lézard10h
NVO Investors are Reminded of Final Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo" or "the Company")  for violations of §§10(b) and 20(a) ...